Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech News -- Ignore unavailable to you. Want to Upgrade?

To: Micro-Selector who wrote (75)	1/27/2000 10:19:00 AM
From: Micro-Selector	Respond to of 7143

BSDM receives CE Mark Approval With market competitors (MSON, VIDA, PHX, CELN, ULGX) trading in $3-8 range, I think this is a strong buy. **************************************** Thursday January 27, 8:07 AM Eastern Time Company Press Release BSD Announces Receipt of CE Mark for Proprietary BSD-2000/3D System; BSD-2000 Approved for Sale in Europe SALT LAKE CITY, Jan. 27 /PRNewswire/ -- BSD Medical (OTC Bulletin Board: BSDM - news) announced today that it has received the CE Mark for its proprietary BSD-2000/3D technology. From a marketing perspective, the CE Mark is the European equivalent to an FDA approval, in that it allows the Company to sell its BSD-2000/3D technology throughout the European community. BSD had already achieved ISO 9001 and ENC 46001 certifications. Hyrum Mead, President of BSD commented, ``Meeting the rigorous standards of the CE Mark for our BSD-2000 System is a critical milestone in our effort to expand world-wide sales of hyperthermia equipment. With the ISO 9001 and ECN 46001 certifications already in place, the CE Mark was the only credential remaining to bring us into compliance with all applicable harmonized EU standards. This is a monumental accomplishment for BSD Medical, and reflects the company's great commitment to standards of excellence and to quality products. Many companies struggle to obtain the CE Mark on comparatively simple products. The BSD-2000/3D is a very complex, sophisticated system. After years of research, development and clinical studies, we are now pleased to offer the European community the BSD-2000/3D, which has been proven to improve disease free survival and quality of life for patients with cancer. With the CE Mark, we can proceed to complete the significant backlog of European orders already received for this product line.' The BSD-2000/3D is the most advanced deep hyperthermia system in the world. It enables 3D electronic adaptive steering of BSD's patented annular phased array (APA) technology. This system has demonstrated clinical utility in localizing treatment to both deep and superficial tumors, including prostate, sarcomas, cervical, breast, gynecological, colorectal, ovarian and other disease sites. The CE Mark approval and the significant reimbursement being paid in some European countries are expected to stimulate European sales. BSD Medical Corporation (BSDM) is the foremost developer and manufacturer of hyperthermia systems for cancer therapy, and pioneer of the non-surgical treatment of benign diseases of the prostate using microwave energy. For further information on BSD, or to find hyperthermic oncology information sources and treatment centers, visit BSD's web site at bsdmc.com. Statements contained in this press release that are not historical facts are forward looking statements, as that item is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties (detailed in the Company's filings with the Securities and Exchange Commission) that could cause actual results to differ materially from estimated results. SOURCE: BSD Medical Corporation